Cipla Remains Upbeat On Abraxane As US Generic Competition Looms
Indian Firm Continuing Talks With FDA For Complex ANDA Product
Executive Summary
Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.
You may also be interested in...
India FY22 Earnings: Everyone’s Talking Of Big Spikes In Input, Logistics Costs
The sharp escalation in prices of raw materials, solvents, excipients and logistics in a volatile operating environment charged by geopolitical tensions and supply chain challenges was one of the key talking points at the fiscal fourth quarter earnings discussions of leading Indian firms. With little hope for respite any time soon, companies are devising strategies to cope.
Apotex Launches Apparent First Abraxane Generic – With Little Fanfare
Apotex has confirmed launch of a generic version of Bristol Myers Squibb’s Abraxane, with details thin on the ground.
Hikma Warns Of Renewed Pricing Pressure On US Generics
Hikma has warned of renewed pressure on generics in the US after a “gradual worsening of the pricing environment” in 2021. However, the company still managed to achieve growth of a tenth in its generics segment last year, on the back of key launches.